心脏骤停后患者目标温度管理降温方法的疗效:系统评价与荟萃分析
该系统评价与荟萃分析比较血管内降温装置(如Thermogard®)与体表降温装置(如Arctic Sun®)在心脏骤停后目标温度管理中对死亡率和神经功能的影响。纳入2项随机对照试验和7项观察性研究,共4401例患者。总体汇总分析显示两组死亡率无统计学显著差异(RR 0.93,95%CI 0.86-1.00,I²=0%),存活者良好神经功能也无统计学显著差异(RR 1.08,95%CI 0.99-1.18,I²=71%)。随机对照试验和观察性研究的亚组分析同样未显示统计学显著差异。研究结论未能证明任一降温装置在生存和神经功能改善方面更有效。
要点
- 总体汇总显示血管内降温装置与体表降温装置死亡率无统计学显著差异(RR 0.93,95%CI 0.86-1.00,I²=0%)。
- 随机对照试验亚组院内死亡率无统计学显著差异(RR 0.80,95%CI 0.56-1.14,I²=0%)。
- 观察性研究亚组院内死亡率无统计学显著差异(RR 0.94,95%CI 0.85-1.04,I²=18%)。
- 存活者良好神经功能总体汇总无统计学显著差异(RR 1.08,95%CI 0.99-1.18,I²=71%)。
- 研究结论未能证明血管内或体表降温装置在生存和神经功能改善方面更有效。
适用人群与场景
- 接受目标温度管理的心脏骤停后患者。
研究设计与关键结果
- 系统评价与荟萃分析,纳入2项随机对照试验和7项观察性研究,共4401例心脏骤停后接受目标温度管理的患者。
- 比较血管内降温装置(如Thermogard®)与体表降温装置(如Arctic Sun®)。
- 总体死亡率汇总分析无统计学显著差异(RR 0.93,95%CI 0.86-1.00,I²=0%)。
- 随机对照试验院内死亡率无统计学显著差异(RR 0.80,95%CI 0.56-1.14,I²=0%)。
- 观察性研究院内死亡率无统计学显著差异(RR 0.94,95%CI 0.85-1.04,I²=18%)。
- 存活者良好神经功能总体汇总无统计学显著差异(RR 1.08,95%CI 0.99-1.18,I²=71%)。
- 随机对照试验出院时良好神经功能无统计学显著差异(RR 0.88,95%CI 0.61-1.28,I²=0%)。
- 观察性研究6个月时良好神经功能无统计学显著差异(RR 1.03,95%CI 0.99-1.09,I²=32%)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入随机对照试验和观察性研究。
- 系统评价注册号:CRD42019129770。
- 局限:原文未报告局限性。
对床旁实践的改变
- 研究结论未能证明血管内降温装置或体表降温装置在心脏骤停后患者生存和神经功能改善方面更有效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This review aimed to compare the efficacy of endovascular cooling devices (ECD), such as Thermogard®, with surface cooling devices (SCD), such as Arctic Sun®, in reducing mortality and improving neurological status for patients with post-cardiac arrest undergoing targeted temperature management.
DATA SOURCES: A systematic literature search was conducted using MEDLINE, EMBASE, and the Cochrane Library to identify randomized controlled trials (RCT) and observational studies (OS) comparing mortality and neurological status for patients treated with ECD or SCD.
RESULTS: The meta-analysis comprised 4,401 patients from 2 RCT and 7 OS. For mortality, the overall pooled analysis showed no statistically significant difference between ECD and SCD recipients (RR, 0.93; 95% CI 0.86-1.00; I2 = 0%). Further, no statistically significant difference was observed between RCT (RR, 0.80; 95% CI 0.56-1.14; I2 = 0%) and OS (RR, 0.94; 95% CI 0.85-1.04; I2 = 18%) for in-hospital mortality. For good neurological status of survivors after TTM, the overall pooled analysis showed no statistically significant difference between ECD and SCD (RR, 1.08; 95% CI 0.99-1.18; I2 = 71%). No statistically significant difference was found between ECD and SCD at hospital discharge in RCT (RR, 0.88; 95% CI 0.61-1.28; I2 = 0%) and at 6 months in OS (RR, 1.03; 95% CI 0.99-1.09; I2 = 32%).
CONCLUSIONS: The study findings could not show that either ECD or SCD was more effective in terms of survival and improved neurological status for post-cardiac arrest patients.
SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42019129770.
参考来源
- Kim JG, Ahn C, Shin H, et al. Efficacy of the cooling method for targeted temperature management in post-cardiac arrest patients: A systematic review and meta-analysis. Resuscitation. 2020. PMID: 31923532. doi:10.1016/j.resuscitation.2019.12.025
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。